@article {FitzGerald351, author = {J. Mark FitzGerald and Lei Wang and R. Kevin Elwood}, title = {Tuberculosis: 13. Control of the disease among aboriginal people in Canada}, volume = {162}, number = {3}, pages = {351--355}, year = {2000}, publisher = {CMAJ}, abstract = {Case 1: A 36-year-old aboriginal woman has a 12-mm-diameter reaction to a tuberculosis (TB) skin test, done as part of a community survey. She was vaccinated with BCG (bacille Calmette-Gu{\'e}rin) at 6 weeks of age. There is no documented history of contact with TB, and no skin tests were carried out previously. The woman{\textquoteright}s family doctor wonders about the significance of the result. Case 2: A 27-year-old aboriginal man presents with a 6-week history of cough and fever and recent onset of hemoptysis. He has recently completed 2 courses of antibiotics, but there has been no improvement in symptoms. Chest radiography shows right upper lobe pneumonia. A further course of antibiotics is prescribed. What investigations should be completed next? Case 3: The mother of a 2-day-old aboriginal infant asks for advice about the benefits of BCG vaccination. She is confused about the side effects of BCG and its effectiveness.}, issn = {0820-3946}, URL = {https://www.cmaj.ca/content/162/3/351}, eprint = {https://www.cmaj.ca/content/162/3/351.full.pdf}, journal = {CMAJ} }